DCTH
DELCATH SYSTEMS, INC.
NASDAQ · Healthcare · Medical - Devices · US
$16.11
−0.86%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$16.24
From 52W high−7.20%
Volume676643.00
Market cap$559.00M
P/E (TTM)1464.5x
P/S (TTM)5.9x
Div yield—
Key dataSep 18, 2026
Open
$16.24
From 52W high
−7.20%
Volume
676643.00
Market cap
$559.00M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
274.7x
P/E (TTM)
1464.5x
RSI (14)
53.6
MomentumView details →
1D Return
−0.86%
YTD Return
+60.20%
SummaryUpdated Jun 1, 2026
Delcath Systems, Inc. (NASDAQ:DCTH) is a specialized interventional oncology company founded in 1988 and headquartered in New York, New York. The company focuses on developing and commercializing innovative treatments for primary and metastatic liver cancers. After decades of development, Delcath achieved a major milestone in 2024 with the U.S. commercial launch of its flagship product HEPZATO KIT, following FDA approval for treating metastatic uveal melanoma. The company also markets its technology in Europe under the CHEMOSAT brand name and is actively expanding its clinical programs to address additional cancer indications.
Similar companies
Latest newsMore news →
Delcath Systems, Inc. reported Q2 2026 earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share.45d agoDelcath Systems dosed the first patient in a Phase 2 clinical trial of HEPZATO for liver-dominant metastatic breast cancer at the European Institute of Oncology in Milan, Italy.73d ago